<DOC>
	<DOCNO>NCT00199394</DOCNO>
	<brief_summary>The purpose study evaluate efficacy 40 mg day istradefylline ( KW-6002 ) reduce percentage awake time spend OFF state patient advance Parkinson 's disease treat levodopa .</brief_summary>
	<brief_title>A Study Istradefylline ( KW-6002 ) Treatment Parkinson 's Disease</brief_title>
	<detailed_description>Parkinson 's disease ( PD ) progressive motor disease characterize bradykinesia akinesia , rigidity , rest tremor . Levodopa still widely use treatment PD , disease progress drug tend become less helpful . This development motor response complication end-of-dose deterioration wearing-off , peak dose dyskinesia , ON-OFF phenomenon . Comparison ( ) : The safety 40 mg/d istradefylline efficacy reduce percentage OFF time patient advance PD treat levodopa compare placebo . The safety efficacy Entacapone also compare placebo .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Istradefylline</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>Patients select study least 30 year age diagnose advanced Parkinson 's disease determine UK Parkinson 's Disease Society ( UKPDS ) criterion Modified Hoehn Yahr Scale . The patient receive levodopa treatment least one year , may take antiparkinsonian drug , average least three hour OFF time record two 24hour ON/OFF diary , female , must nonpregnant nonnursing . Patients may enrol take certain medication exclude protocol , treat investigational drug within 30 day prior randomisation ( five halflives longer ) , ever receive istradefylline treat COMT inhibitor , psychotic , clinically significant illness laboratory value screen , insufficient mental capacity comply protocol requirement certain psychiatric neurological condition .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>KW-6002 ( istradefylline )</keyword>
	<keyword>Entacapone</keyword>
	<keyword>Placebo</keyword>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Motor Response Complications</keyword>
	<keyword>Levodopa Therapy</keyword>
</DOC>